800 CHESAPEAKE DRIVE, REDWOOD CITY, CA
Reports Positive Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia and Business Update
Ex-99.1
Shareholder votes
Investor Presentation
CFO Departure - Vishwas Setia Separated from MapLight Therapeutics
Reports First Quarter 2026 Financial Results and Provides Business Update
Board Changes - Dr. Malenka and Dr. Trenkle Not Standing for Reelection
Annual Report to Security Holders
Q2
FY 2025
Q3
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities to be Offered to Employees
Certificate
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Free Writing Prospectus